Sharon Mates - 14 Oct 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman, President & CEO, Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
14 Oct 2021
Net transactions value
-$1,996,947
Form type
4
Filing time
18 Oct 2021, 18:00:39 UTC
Previous filing
24 Aug 2021
Next filing
11 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Sale $56,640 -1,416 -0.12% $40.00 1,141,976 14 Oct 2021 Direct F1
transaction ITCI Common Stock Sale $1,615,680 -40,392 -3.5% $40.00 1,101,584 15 Oct 2021 Direct F1
transaction ITCI Common Stock Options Exercise $3,053 +1,075 +0.1% $2.84* 1,102,659 15 Oct 2021 Direct
transaction ITCI Common Stock Sale $327,680 -8,192 -0.74% $40.00 1,094,467 18 Oct 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -1,075 -2.7% $0.000000 38,925 15 Oct 2021 Common Stock 1,075 $2.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 All shares underlying this option have vested.